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ABSTRACT: Multi-target design offers access to bioactive small molecules with potentially superior efficacy and safety. Par-
ticularly multifactorial chronic inflammatory diseases demand multiple pharmacological interventions for stable treatment. 
By minor structural changes, we have developed a close analogue of the cysteinyl-leukotriene receptor antagonist zafirlukast 
that simultaneously inhibits soluble epoxide hydrolase and activates peroxisome proliferator-activated receptor γ. The triple 
modulator exhibits robust anti-inflammatory activity in vivo and highlights the therapeutic potential of designed multi-target 
agents. 
INTRODUCTION 
Though anti-inflammatory drug discovery is very inten-
sive1, inflammatory diseases remain amongst the most seri-
ous health burdens and there is unmet medical need for 
more efficacious anti-inflammatory drugs. The number of 
drugged targets in inflammatory diseases is constantly 
growing but especially in the most severe, chronic disorders 
even innovative agents fail to produce sufficient therapeutic 
efficacy1. As a very complex pathophysiological process, in-
flammation involves a myriad of enzymes, mediators and 
receptors and pharmacological modulation of a single tar-
get tends to cause shunting effects that compromise thera-
peutic efficacy2. Thus, robust anti-inflammatory therapies 
often require the use of multiple drugs but considering the 
drawbacks of excessive polypharmacy, a multi-target anti-
inflammatory agent seems a superior approach. 
RESULTS & DISCUSSION 
To generate such multi-target anti-inflammatory agent, 
we selected the cysteinyl leukotriene receptor 1 
(CysLT1R)3,4 antagonist zafirlukast (1)5 for which we have 
Figure 1. Docking analysis of the lead compound’s (1) binding mode in the PPARγ ligand binding domain (A, PDB-ID: 3WMH) and 
the sEH active site (B, PDB-ID: 5ALZ). Detailed views of the individual molecular building blocks and docking-derived structural 
modifications are shown in Figures S1&S2. 
 observed moderate off-target activity (Table 1) on the pe-
roxisome proliferator-activated receptor γ (PPARγ)6 and 
the soluble epoxide hydrolase (sEH)7. Like CysLT1R, PPARγ 
and sEH interact with metabolites of arachidonic acid and 
hold great anti-inflammatory potential1 and their selective 
modulation reduced acute inflammation in animal mod-
els8,9. The weak side-activities of the fatty acid mimetic10 1, 
therefore, seem supportive of an anti-inflammatory efficacy 
and we aimed to optimize the PPARγ agonistic and sEH in-
hibitory activity of 1 while retaining CysLT1R antagonism to 
generate a triple modulator that simultaneously addresses 
three anti-inflammatory targets. 
To establish a strategy for structural optimization, we an-
alyzed the putative binding mode of 1 in the PPARγ ligand 
binding domain (PDB-ID: 3WMH) and the sEH C-terminal 
domain (PDB-ID: 5ALZ11) by molecular docking (Figure 1, 
detailed view in Figures S1&S2). Examination of the best 
scored poses suggested that minor changes would allow 
marked improvements in potency. Spatial extension of the 
urethane cyclopentyl substituent to a six-membered ring 
seemed favorable for PPARγ and sEH binding since the ure-
thane O-substituent protruded into lipophilic sub-pockets 
of both targets which offered additional space for a larger 
ring. Moreover, caused by its ortho-methyl residue, the 
phenylsulfonamide obtained a dihedral conformation that 
was disfavored by PPARγ and might be resolved through a 
free ortho-position which was supported by strain energy 
calculations (Table S1). Interaction potential analysis in the 
phenylsulfonamide binding region in the PPARγ ligand 
binding site, furthermore, suggested opportunities for opti-
mization in meta- or para-substitution of said ring with 
small halogens. And finally, replacement of the urethane 
moiety in 1 by urea appeared to optimize sEH inhibitory po-
tency by adding a further H-bond donor that would enable 
an additional H-bond towards Asp335. Guided by these in 
silico observations, we prepared analogues of 1 with small 
but concerted structural changes to enhance triple potency. 
Analogues 2-10 were prepared in an eight-step synthetic 
procedure adopted from a published12 approach to 1 with 
suitable modifications (Scheme 1). In brief, N-methyl-5-ni-
troindole (11) was available from 12 by methylation with 
DMS. Esterification of 13 followed by radical bromination 
yielded building block 14 which was coupled with 11 to 15 
under Friedel-Craft conditions using FeCl3 as catalyst. After 
reducing 15 with H2 and Pd(C) to aniline 16, urethane 17 
was available from 16 and chloroformate 18 while reaction 
of 16 with isocyanates 19 and 20 produced ureas 21 and 
22. Finally, ester hydrolysis in 17, 21 and 22 to free acids 
23-25 followed by sulfonamide coupling with DCC/DMAP 
and 26-30 afforded 2-10 in 8-12% overall yield. 
PPARγ agonistic potency of analogues 2-10 was quanti-
fied in a specific reporter gene assay13 in HEK293T cells 
Scheme 1. Synthesis of 2-10. Reagents & conditions: (a) Me2SO4, dioxane, 40 °C, 2.5 h; (b) MeOH, SOCl2, reflux, 4 h; (c) CHCl3, AIBN, 
NBS, reflux, 4 h; (d) FeCl3, dioxane, r.t. 12 h; (e) H2, Pd(C), MeOH, r.t. 12 h; (f) THF, DIPEA, C5H9-OCOCl (18), 4 °C -> r.t., 4 h; (g) THF, 
DBU, C6H11-NCO (19) or C5H9-NCO (20), 40 °C, 12 h; (h) LiOH, MeOH/H2O, r.t., 16 h; (i) CHCl3, DCC, DMAP, R2-Ph-SO2NH2 (26-30), 
reflux, 12 h. 
 based on a hybrid receptor comprising the PPARγ-LBD and 
the DNA-binding domain of the nuclear receptor Gal4 from 
yeast. Inhibition of sEH was determined in a fluorescence-
based assay14 with recombinant protein and PHOME as flu-
orogenic substrate. A cellular leukotriene D4 induced Ca2+-
influx assay in Cos-7 cells transiently overexpressing 
CysLT1R15 served to characterize antagonistic potency of 2-
10 on CysLT1R (Table 1).  
Based on our docking study, we replaced the urethane 
moiety of 1 by a urea (2) which expectedly was accompa-
nied by a significant improvement in sEH inhibitory potency 
while CysLT1R antagonism dropped dramatically. On 
PPARγ, replacement of the urethane moiety by urea hardly 
affected the EC50 value but significantly diminished transac-
tivation efficacy.  Considering that weight gain is a common 
adverse effect of full PPARγ agonists and that partial ago-
nists lack this undesired activity while retaining anti-in-
flammatory effects of PPARγ modulation16–18, partial ago-
nistic activity on PPARγ appears favorable and safer.  
Ring expansion from cyclopentylurea 2 to cyclohexylurea 
3 further promoted sEH inhibition and markedly improved 
PPARγ agonism but was poorly tolerated concerning 
CysLT1R antagonism. Variations in the sulfonamide moiety 
were better tolerated by CysLT1R with unsubstituted 
phenylsulfonamide 4 and 3-chlorophenylsulfonamide 5 re-
taining a pA2 value above 10. As suggested by the proposed 
binding mode, the freely rotatable phenylsulfonamides 4 
and 5 strongly enhanced PPARγ agonistic potency. Inhibi-
tory potency on sEH was hardly affected by changes in the 
sulfonamide region. Thus, we combined cyclohexylurea (3) 
and 3-chlorophenylsulfonamide (5) as most favorable mod-
ifications for sEH inhibition and PPARγ agonistic potency, 
respectively. The resulting compound 6 comprised bal-
anced triple modulatory potency on PPARγ, sEH and 
CysLT1R. Introduction of a second chlorine atom in 7 and 
replacement of chlorine by trifluoromethyl (8) failed to im-
prove the triple activity while replacement of chlorine by 
fluorine (9) was slightly favored by PPARγ and sEH but not 
by CysLT1. Intriguingly, the most favorable triple activity 
profile was achieved with unsubstituted phenylsulfona-
mide 10. As assumed from the proposed binding poses, 
three minor structural changes were sufficient to generate 
a triple modulator with nanomolar potency on PPARγ, sEH 
and CysLT1R. 
Off-target profiling of 1 and 10 on nuclear receptors (Fig-
ure S3A) revealed significantly reduced off-target activity 
for the triple modulator 10 despite its designed polyphar-
macological profile while 1 turned out remarkably unselec-
tive. Especially its agonistic activity on pregnane X receptor 
(PXR) and constitutive androstane receptor (CAR) may 
compromise the safety of 1 since these xenobiotic receptors 
drive cytochrome P450 expression, promote drug metabo-
lism and can be a basis of drug-drug interactions19,20. In con-
trast to 1, the triple modulator 10 was inactive on CAR and 
only weakly activated PXR. 
Moreover, the triple modulator 10 comprised remarka-
bly higher aqueous solubility (10: 2.1 mg/L; 1: 0.14 mg/L) 
and a lower logD7.4 value (10: 1.70; 1: 2.47) than 1, and was 
considerably less toxic (Figure S3B-D). Microsomal stability 
was high for both, 10 and lead structure 1 with 65% and 
73%, respectively, remaining after 4 hours incubation (Fig-
ure S1E). Under cellular conditions, 10 robustly inhibited 
sEH product formation in HepG2 homogenates with an IC50 
value of 14±2 nM and induced PPARγ target gene expres-
sion in HepG2 cells (Figure 2A/B). However, in contrast to 
PPARγ agonist rosiglitazone, 10 did not induce adipocyte 
differentiation and failed to induce PPARγ regulated gene 
expression in this cell-type (Figure 2C/D). Thus, 10 com-
prises a non-adipogenic, selective PPARγ modulatory pro-
file as it has been observed for other PPARγ ligands18. 
Pilot in vivo evaluation of 10 in four wild-type male 
C57Bl6/J mice (Figure 3A-C) revealed a favorable pharma-
cokinetic profile after oral application of 10 mg/kg 10 with 
rapid uptake, good bioavailability and a terminal half-life of 
1.9 h resulting in effective concentrations for PPARγ activa-
tion over approx. 4 h. Sufficient concentrations of 10 for sEH 
inhibition and CysLT1R antagonism were still detectable af-
ter 8 h. The EET/DHET ratio was significantly shifted to-
wards sEH substrates 8 h post dose and of expression 
PPARγ target gene CD36 was upregulated in mouse livers 
compared to vehicle treated animals. 
 
Table 1. In vitro activity of 1-10 on PPARγ, sEH and CysLT1R. Results are mean±SEM, n≥3. 
 
PPARγ 
EC50 [µM]  
(max. rel. act. [%]) 
sEH 
IC50 [µM] 
CysLT1R 
(pA2) ID R1 X R2 
1 C5H9 O 2-CH3 2.44±0.09 (129±4) 2.0±0.3 11.4±0.1 
2 C5H9 NH 2-CH3 2.49±0.09 (21±1) 0.59± 0.06 9.1±0.1 
3 C6H11 NH 2-CH3 0.67±0.05 (47±1) 0.15±0.01 7.6±0.1 
4 C5H9 O H 0.23±0.05 (140±8) 2.5±0.8 10.1±0.1 
5 C5H9 O 3-Cl 0.14±0.01 (73±1) 7±2 10.0±0.1 
6 C6H11 NH 3-Cl 0.37±0.03 (18±1) 0.68±0.06 8.9±0.1 
7 C6H11 NH 3,5-Cl2 0.74±0.03 (29±1) 0.55±0.01 8.2±0.2 
8 C6H11 NH 3-CF3 0.35±0.05 (18±1) 1.49±0.09 8.3±0.1 
9 C6H11 NH 3-F 0.20±0.02 (21±1) 0.41±0.02 7.9±0.1 
10 C6H11 NH H 0.30±0.02 (36±1) 0.043±0.002 8.7±0.1 
       
 Encouraged by the favorable in vitro and pilot in vivo data, 
we studied anti-inflammatory activity of 10 in the model of 
paw edema induced by intraplantar injection of zymosan in 
mice, which closely mimics the symptoms of inflammation 
in man21 (Figure 3D). 1 (10 mg/kg), 10 (10 mg/kg) or vehi-
cle were administered orally 30 min prior to zymosan, and 
the paw edema was assessed by plethysmometry. 8 h after 
zymosan injection, the paw edema was indistinguishable 
between groups. 24 h after zymosan injection, the paw 
edema was significantly reduced in mice treated with 10 
compared to vehicle-treated mice whereas 1 did not affect 
the extent of paw edema. Control experiments revealed no 
change in paw size in the contralateral hindpaw. These data 
confirm that 10 exerts anti-inflammatory effects in vivo and 
that triple target modulation of 10 is superior to 1. 
PPARγ activation9, e.g. with the full agonist rosiglitazone, 
as well as sEH inhibition8 have revealed some therapeutic 
efficacy in animal models of acute inflammation similar to 
the paw edema model used in our study. Designing PPARγ 
agonistic and sEH inhibitory activity into 1 provided the tri-
ple modulator 10 with significantly superior anti-inflamma-
tory effects compared to 1 in a murine model of acute in-
flammation. Notably, 10 only exhibits partial PPARγ ago-
nism which proved sufficient to achieve this anti-inflamma-
tory activity underlining a great advantage of multi-target 
modulation. When supportive target combinations are ad-
dressed simultaneously, partial modulation of these targets 
can be sufficient to achieve the desired therapeutic effects 
which may allow the development of multi-target com-
pounds with high efficacy and reduced adverse activity2. 
The triple modulatory potency of 10 may be of therapeu-
tic value in a variety of diseases involving inflammatory 
processes. Particularly, in allergic asthma for which 1 is ap-
proved, PPARγ plays a central role in the regulation of air-
way inflammation involving modulation of IL-17 produc-
tion22 and eosinophil differentiation23. Accordingly, PPARγ 
agonists showed therapeutic efficacy in animal models of al-
lergic asthma including anti-inflammatory and bronchodi-
latory activity22,24,25. Even a correlation of PPARγ polymor-
phisms with asthma development has been reported26. 
Moreover, sEH inhibition reduced allergic airway inflamma-
tion and hyperresponsiveness in ovalbumin induced 
asthma in mice27 suggesting that all three molecular targets 
of 10 are suitable to treat allergic asthma.  
Beyond asthma, chronic obstructive pulmonary disease 
(COPD) may also markedly profit from PPARγ activation 
combined with inhibition of CysLT1R and sEH. Recent clini-
cal observations have found decreased expression of PPARγ 
in lung tissue of COPD patients28 and reduced COPD exacer-
Figure 3. In vivo pharmacological characterization of triple modulator 10: Pharmacokinetic profiling of 10 after a 10 mg/kg p.o. 
dose revealed rapid uptake, high bioavailability and a half-life of 2 h (A, results are mean±SEM; n=4). In healthy male wild-type 
C57BL6/J mice, 10 increased plasma sEH substrate/product ratio (B) and modulated hepatic transcription of PPARγ target gene 
CD36 (C, results are mean±SEM; n(vehicle)=2, n(10)=4). In the paw edema model in C57BL/6N mice pretreated with vehicle, 1 or 
10 30 min prior to zymosan injection into one hindpaw (D), 10 significantly reduced paw edema after 24 h suggesting anti-inflam-
matory potency in vivo and was superior to lead compound 1 confirming increased efficacy through designed multi-target activity 
(solid lines - ipsilateral paw; dotted lines - contralateral paw; results are mean±SEM; n=6). * p < 0.05. 
Figure 2. In vitro pharmacological characterization of triple modulator 10: (A) 10 inhibits sEH product formation with an IC50 value 
of 14±2 nM in HepG2 cells. (B) Moreover, 10 induces PPARγ target gene transcription in HepG2 cells. (C/D) However, 10 does not 
promote adipocyte differentiation (C) or PPARγ target gene transcription in 3T3-L1 mouse fibroblasts (D). Results are mean±SEM, 
n=4, * p < 0.05, ** p < 0.01, p < 0.001. CIU - N-cyclohexyl-N’-(4-iodophenyl)urea. 
 bations in patients receiving PPARγ agonistic thiazoli-
dinediones29. Moreover, treatment with CysLT1R antago-
nist 1 improved the lung function of COPD patients30 and 
sEH inhibitors possessed therapeutic efficacy in COPD 
mouse models31,32. The rational combination of simultane-
ously modulating these three biological targets with a single 
molecule may, therefore, produce superior therapeutic effi-
cacy in COPD. 
CONCLUSION 
The development of triple modulator 10 and its activity 
profile compared to 1 highlight the remarkable impact of 
very minor structural changes on a drug’s effects and effi-
cacy. Concerted optimization of intrinsic off-target activities 
of 1 generated the potent triple modulator 10 which by 
modulating three individual anti-inflammatory targets 
comprises significantly enhanced anti-inflammatory po-
tency in vivo while conserving the lead compound's struc-
tural properties, molecular weight and pharmacokinetic 
profile. This alternative interpretation of selective optimi-
zation of side-activities33 might hold great potential for nu-
merous drug molecules, especially in times of increasing 
polypharmacy. 
EXPERIMENTAL 
General. All final compounds (2-10) for biological evaluation 
had a purity of >95% according to HPLC-UV analysis at wave-
lengths 245 and 280 nm. 
Preparation and analytical characterization of triple modu-
lator 10 and intermediates:  
4-((5-(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl)me-
thyl)-3-methoxy-N-(phenylsulfonyl)benzamide (10): 4-
((5-(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl)methyl)-3-
methoxybenzoic acid (24, 50 mg, 0.11 mmol, 1.00 eq) was dis-
solved in chloroform (abs., 10 mL) and benzenesulfonamide 
(26, 23 mg, 0.15 mmol, 1.30 eq), dicyclohexyl carbodiimide (35 
mg, 0.17 mmol, 1.50 eq) and 4-(N,N-dimethylamino)pyridine 
(14 mg, 0.11 mmol, 1.00 eq) were added and the mixture was 
stirred under reflux for 12 h. After cooling to room tempera-
ture, 10 mL 5% aqueous hydrochloric acid were added, phases 
were separated, and the aqueous layer was extracted with 
EtOAc (3x10 mL). The combined organic layers were dried 
over Na2SO4 and the solvents were evaporated under reduced 
pressure. The crude product was purified by column chroma-
tography using EtOAc/hexane/acetic acid (9:89:2) as mobile 
phase. The residue was then dissolved in 0.5 mL methanol, 10 
mL water were added, and the suspension was immediately 
frozen and lyophilized to yield the title compound as colorless 
solid (50 mg, 76%). 1H NMR (400 MHz, CDCl3) δ = 8.15 (dd, J = 
1.6, 1.6 Hz, 1H), 8.12 (dd, J = 1.7, 1.7 Hz, 1H), 7.67 – 7.58 (m, 
1H), 7.53 (dd, J = 7.7, 7.7 Hz, 2H), 7.34 (d, J = 1.6 Hz, 2H), 7.27 
(d, J = 1.9 Hz, 1H), 7.25 – 7.21 (m, 2H), 7.07 (d, J = 7.9 Hz, 1H), 
7.01 (dd, J = 8.6, 1.9 Hz, 1H), 6.85 (s, 1H), 4.65 (d, J = 7.1 Hz, 1H), 
4.03 (s, 2H), 3.87 (s, 3H), 3.74 (s, 3H), 1.85 – 1.77 (m, 2H), 1.62 
– 1.46 (m, 3H), 1.34 – 1.20 (m, 5H). 13C NMR (126 MHz, DMSO-
d6) δ = 165.12, 156.69, 154.98, 139.58, 135.39, 133.67, 132.82, 
132.41, 129.32, 129.16, 128.33, 127.70, 127.40, 120.75, 114.28, 
110.61, 110.05, 109.55, 107.52, 55.71, 47.59, 33.16, 32.32, 
29.63, 25.31, 24.74, 24.45. MS (ESI-): m/z 573.24 [M-H]-. HRMS 
(MALDI): m/z calculated for C31H34N4O5SNa 597.21421, found 
597.21292 [M+Na]+. 
1-Methyl-5-nitro-1H-indole (11): 5-Nitro-1H-indole (12, 
2.45 g, 15.1 mmol, 1.0 eq) was dissolved in 100 mL DMF, NaOH 
(1.28 g, 32.0 mmol, 2.1 eq) was added and the mixture was 
stirred for 10 min at 40 °C. Dimethyl sulfate (1.68 mL, 17.7 
mmol, 1.2 eq) was carefully added and the mixture was stirred 
for another 2 h at 40 °C. Then, H2O was added to precipitate the 
title compound as a yellow solid (6.12 g, 23%). 1H NMR (250 
MHz, DMSO-d6) δ = 8.55 (d, J = 2.2 Hz, 1H), 8.02 (dd, J = 9.1, 2.3 
Hz, 1H), 7.62 (d, J = 9.1 Hz, 1H), 7.58 (d, J = 3.2 Hz, 1H), 6.73 (dd, 
J = 3.2, 0.6 Hz, 1H), 3.86 (s, 3H). MS (ESI+): no molecular ion. 
Methyl 3-methoxy-4-methylbenzoate (14a): 3-Methoxy-4-
methylbenzoic acid (13, 5.00 g, 30.1 mmol, 1.0 eq) was dis-
solved in MeOH (abs., 150 mL). Thionyl chloride (3.30 mL, 45.5 
mmol, 1.5 eq) was carefully added, and the mixture was re-
fluxed for 6 h. 50 mL 2 N aqueous hydrochloric acid were then 
added, and the mixture was extracted with CHCl3 (3x50 mL). 
The combined organic layers were dried over MgSO4 and the 
solvent was evaporated in vacuum to obtain the title compound 
as a colorless solid (4.26 g, 79%). 1H NMR (250 MHz, DMSO-d6) 
δ = 7.47 (d, J = 7.7 Hz, 1H), 7.42 (s, 1H), 7.27 (d, J = 7.7 Hz, 1H), 
3.84 (s, 6H), 2.20 (s, 3H). MS (ESI+): no molecular ion. 
Methyl 4-(bromomethyl)-3-methoxybenzoate (14): Methyl 
3-methoxy-4-methylbenzoate (14a, 4.26 g, 23.7 mmol, 1.0 eq) 
was dissolved in 150 mL CHCl3. N-Bromosuccinimide (5.12 g, 
28.8 mmol, 1.2 eq) and azobisisobutyronitrile (377 mg, 2.3 mol, 
0.1 eq) were added and the mixture was refluxed for 12 h. After 
cooling to room temperature, the precipitated title compound 
was filtered off as a colorless solid (3.81 g, 73%). 1H NMR (250 
MHz, DMSO-d6) δ = 7.56 – 7.49 (m, 3H), 4.66 (s, 2H), 3.92 (s, 
3H), 3.86 (s, 3H). MS (ESI+): no molecular ion. 
Methyl 3-methoxy-4-((1-methyl-5-nitro-1H-indol-3-
yl)methyl)benzoate (15): 1-Methyl-5-nitro-1H-indole (11, 
699 mg, 4.00 mmol, 1.0 eq) and methyl 4-(bromomethyl)-3-
methoxybenzoate (14, 1.00 g, 4.00 mmol, 1.0 eq) were dis-
solved in 1,4-dioxane (abs., 50 mL), FeCl3 (1.94 g, 12.0 mmol, 
3.0 eq) was carefully added, and the mixture was stirred at 
room temperature for 12 h. The mixture was then filtered 
through celite, the filtrate was dried over MgSO4, and the sol-
vent was evaporated in vacuum. Further purification was per-
formed by column chromatography using n-hexane/EtOAc 
(5:1) as mobile phase to obtain the title compound as yellow 
solid (0.53 g, 38%). 1H NMR (250 MHz, DMSO-d6) δ = 8.50 (d, J 
= 2.2 Hz, 1H), 8.02 (dd, J = 9.1, 2.3 Hz, 1H), 7.59 (d, J = 9.1 Hz, 
1H), 7.53 – 7.45 (m, 2H), 7.37 (s, 1H), 7.28 (d, J = 8.3 Hz, 1H), 
4.12 (s, 2H), 3.92 (s, 3H), 3.83 (s, 3H), 3.81 (s, 3H). MS (ESI+): 
m/z 377.05 [M+Na]+. 
Methyl 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-
methoxybenzoate (16): Methyl 3-methoxy-4-((1-methyl-5-
nitro-1H-indol-3-yl)methyl)benzoate (15, 0.17 g, 0.50 mmol, 
1.0 eq) was dissolved in 10 mL EtOH and Pd(C) (53 mg, 0.05 
mmol, 0.1 eq) was added. The suspension was stirred at room 
temperature under H2 atmosphere for 12 h. The mixture was 
then filtered through celite, the filtrate was dried over MgSO4, 
and the solvent was evaporated in vacuum to obtain the title 
compound as pale purple solid (0.15 g, 94%). 1H NMR (250 
MHz, DMSO-d6) δ = 7.53 – 7.41 (m, 2H), 7.16 – 7.01 (m, 2H), 
6.88 (s, 1H), 6.59 – 6.48 (m, 2H), 4.44 (br s, 2H), 3.95 – 3.87 (m, 
5H), 3.83 (s, 3H), 3.62 (s, 3H). MS (ESI+): m/z 325.19 [M+H]+. 
Methyl 4-((5-(3-cyclohexylureido)-1-methyl-1H-indol-3-
yl)methyl)-3-methoxybenzoate (21): Methyl 4-((5-amino-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (16, 487 
 mg, 1.50 mmol, 1.00 eq) was dissolved in THF (abs., 22 mL) and 
DBU (abs., 0.75 mL) was added. Cyclohexylisocyanate (19, 281 
mg, 2.25 mmol, 1.50 eq) was added dropwise and the mixture 
was stirred at 40°C for 12 h. 30 mL 1% aqueous hydrochloric 
acid were added and the mixture was stirred for another 5 
minutes. After addition of 15 mL EtOAc phases were separated 
and the aqueous layer was extracted with EtOAc (2x30 mL). 
The combined organic layers were dried over Na2SO4 and the 
solvents were evaporated under reduced pressure. The crude 
product was purified by column chromatography using 
EtOAc/hexane (1:4) as mobile phase to yield the title com-
pound as colorless solid (330 mg, 49%). 1H NMR (400 MHz, 
DMSO-d6) δ = 8.03 (s, 1H), 7.50 (d, J = 1.3 Hz, 2H), 7.46 (dd, J = 
7.8, 1.5 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 
7.05 (dd, J = 8.7, 1.9 Hz, 1H), 7.02 (s, 1H), 5.86 (d, J = 7.8 Hz, 1H), 
3.96 (s, 2H), 3.93 (s, 3H), 3.84 (s, 3H), 3.69 (s, 3H), 3.53 – 3.39 
(m, 1H), 1.85 – 1.76 (m, 2H), 1.71 – 1.62 (m, 2H), 1.59 – 1.50 (m, 
1H), 1.38 – 1.07 (m, 5H). MS (ESI+): m/z 450.1 [M+H]+. 
4-((5-(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl)me-
thyl)-3-methoxybenzoic acid (24): Methyl 4-((5-(3-cyclo-
hexylureido)-1-methyl-1H-indol-3-yl)methyl)-3-methoxyben-
zoate (21, 310 mg, 0.69 mmol, 1.00 eq) was dissolved in meth-
anol (6 mL), water (12 mL) and lithium hydroxide (198 mg, 
8.28 mmol, 12.0 eq) were added and the mixture was stirred at 
room temperature for 16 h. After acidification with 20 mL 10% 
aqueous hydrochloric acid, the mixture was extracted with 
EtOAc (3x25 mL). The combined organic layers were dried 
over Na2SO4 and the solvents were evaporated under reduced 
pressure. The crude product was purified by column chroma-
tography using EtOAc/hexane/acetic acid (19:79:2) as mobile 
phase to yield the title compound as colorless solid (265 mg, 
88%).1H NMR (500 MHz, DMSO-d6) δ = 8.03 (s, 1H), 7.48 (d, J = 
1.6 Hz, 2H), 7.42 (dd, J = 7.8, 1.5 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 
7.09 (d, J = 7.8 Hz, 1H), 7.04 (dd, J = 8.7, 2.0 Hz, 1H), 7.00 (s, 1H), 
5.86 (d, J = 7.9 Hz, 1H), 3.94 (s, 2H), 3.90 (s, 3H), 3.68 (s, 3H), 
3.45 – 3.41  (m, 1H), 1.82 – 1.75 (m, 2H), 1.65 (dd, J = 9.1, 4.1 
Hz, 2H), 1.53 (dd, J = 8.5, 4.1 Hz, 1H), 1.34 – 1.23 (m, 2H), 1.21 
– 1.08 (m, 3H). MS (ESI-): m/z 434.29 [M-H]-. 
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ABBREVIATIONS 
AIBN, 2,2’-azobis(2-methylpropionitrile); CD36, cluster of dif-
ferentiation 36; CAR, constitutive androstane receptor; CIU, N-
cyclohexyl-N’-(4-iodophenyl)urea; CysLT1R, cysteinyl leukotri-
ene receptor 1; DCC, dicyclohexylcarbodiimide; DHET, dihy-
droxyeicosatrienoic acid; DIPEA, N,N-diisopropylethylamine; 
DMAP, 4-(dimethylamino)pyridine; DMS, dimethyl sulfate; 
DNA, deoxyribonucleic acid; EC50, half maximal effective con-
centration; EET, epoxyeicosatrienoic acid; EtOAc, ethyl acetate; 
HEK293T, human embryonic kidney cells 293T; HepG2, human 
hepatoma cells; IC50, half maximal inhibitory concentration; 
LBD, ligand binding domain; NBS, N-bromosuccinimide; 
PHOME, 3-phenylcyano-(6-methoxy-2-naphthalenyl)-2-
oxiraneacetic   acid methyl ester; PPAR, peroxisome prolifera-
tor-activated receptor; PXR, pregnane x receptor; THF, tetrahy-
drofuran; sEH, soluble epoxide hydrolase; SEM, standard error 
of the mean. 
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